Overview

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
0
Participant gender:
All
Summary
High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Leudosite
Treatments:
Alemtuzumab
Criteria
Inclusion Criteria:

1. 15-65 years old

2. B or T-cell lymphoid disease, not eligible for non-myeloablative transplantation.

3. Patients in relapse after failing conventional chemotherapy.

4. Patients with HLA-identical or one-antigen mismatched sibling, or a matched unrelated
donor.

5. Performance status
Exclusion Criteria:

1. Past history of anaphylaxis following exposure to rat or mouse derived CDR-grafted
humanized monoclonal antibodies.

2. Less than 4 weeks since prior chemotherapy.

3. Pregnancy or lactation.

4. HIV or HTLV-I positivity.

5. Serum creatinine >1.6 mg/dl or serum bilirubin >0.2 mg/dl unless due to tumor, SGPT
>/= 2 x NI

6. PFT-DCLO<50%, cardiac EF <50% of predicted levels.